Literature DB >> 21376243

Comparing ranibizumab with bevacizumab.

Partha Biswas, Subhrangshu Sengupta, Ruby Choudhary, Subhankar Home, Ajoy Paul, Sourav Sinha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21376243     DOI： 10.1016/j.ophtha.2010.10.027

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  6 in total

1.  Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis.

Authors:  Joel Hanhart; Doron S Comaneshter; Yossi Freier-Dror; Shlomo Vinker
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-10       Impact factor: 3.117

2.  FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.

Authors:  Jordi Monés; Marc Biarnés; Fabio Trindade; Ricardo Casaroli-Marano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-15       Impact factor: 3.117

Review 3.  Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials.

Authors:  Laurent Kodjikian; Evelyne Decullier; Eric H Souied; Jean-François Girmens; Emilie E Durand; François R Chapuis; Laure Huot
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-22       Impact factor: 3.117

4.  Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.

Authors:  Ba' Pham; Sonia M Thomas; Erin Lillie; Taehoon Lee; Jemila Hamid; Trevor Richter; Ghayath Janoudi; Arnav Agarwal; Jane P Sharpe; Alistair Scott; Rachel Warren; Ronak Brahmbhatt; Erin Macdonald; Sharon E Straus; Andrea C Tricco
Journal:  BMJ Open       Date:  2019-05-28       Impact factor: 2.692

Review 5.  Changing paradigms of anti-VEGF in the Indian scenario.

Authors:  P Mahesh Shanmugam
Journal:  Indian J Ophthalmol       Date:  2014-01       Impact factor: 1.848

Review 6.  The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

Authors:  Edith Poku; John Rathbone; Ruth Wong; Emma Everson-Hock; Munira Essat; Abdullah Pandor; Allan Wailoo
Journal:  BMJ Open       Date:  2014-07-17       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.